Akebia Therapeutics, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
151.04 |
200.93 |
289.11 |
307.67 |
403.99 |
503.18 |
| Przychód Δ r/r |
0.00% |
33.04% |
43.88% |
6.42% |
31.30% |
24.55% |
| Przychód (min) |
147.00 |
195.42 |
216.91 |
268.15 |
352.09 |
438.54 |
| Przychód (max) |
155.07 |
206.45 |
395.55 |
361.76 |
475.00 |
591.62 |
| EBITDA (średnia) |
-68.53 |
-91.18 |
-131.19 |
-139.61 |
-183.31 |
-228.32 |
| EBIT (średnia) |
-84.95 |
-113.01 |
-162.60 |
-173.04 |
-227.21 |
-283.00 |
| EBIT % |
-56.24% |
-56.24% |
-56.24% |
-56.24% |
-56.24% |
-56.24% |
| Zysk netto (średni) |
-64.45 |
-12.23 |
21.87 |
20.96 |
87.19 |
109.69 |
| Zysk netto % |
-42.67% |
-6.09% |
7.56% |
6.81% |
21.58% |
21.80% |
| EPS (średnia) |
-0.31 |
-0.06 |
0.09 |
0.08 |
0.41 |
0.52 |
| Liczba analityków (Przychody) |
2 |
3 |
5 |
4 |
2 |
3 |
| Liczba analityków (EPS) |
2 |
2 |
3 |
4 |
3 |
2 |
| symbol |
AKBA |
AKBA |
AKBA |
AKBA |
AKBA |
AKBA |